Abstract: SA-PO530
Long-Term Prognosis of Kidney Transplant Patients with Rapidly Progressive Glomerulonephritis (RPGN)
Session Information
- Immunosuppression, Disease Recurrence, and Malignancy
November 04, 2017 | Location: Hall H, Morial Convention Center
Abstract Time: 10:00 AM - 10:00 AM
Category: Transplantation
- 1702 Transplantation: Clinical and Translational
Authors
- Kharadjian, Talar, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin, United States
- Astor, Brad C., University of Wisconsin, Madison, Wisconsin, United States
- Panzer, Sarah E., School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin, United States
- Singh, Tripti, School of Medicine and Public Health, University of Wisconsin , Madison, Wisconsin, United States
Background
ANCA associated vasculitis (AAV) and anti-GBM are the leading cause of ESRD due to RPGN. We report our institution’s experience with renal transplant patients in patients with ESRD due to RPGN.
Methods
We compared the outcomes for patients with ESRD due biopsy-proven AAV and anti-GBM with patients with ESRD due to IgA nephropthy (IgAN) and autosomal dominant polycystic kidney disease (ADPKD) who underwent kidney transplant between 1994 to 2013.
Results
72 patients with biopsy proven RPGN (AAV N=46, anti-GBM N=26) underwent kidney transplant between 1994-2013. The mean follow up time was 7.2 years (± 4.7 years). The incidence of graft loss was 2.9/100 person years for AAV and 5.2/100 persons year for anti-GBM. The incidence of patient death was 3.8/100 person years for AAV and 3.2/100 person years for anti-GBM. The risks of graft loss and patient death were similar to those for IgAN (2.8 and 2.2/100 person years) in multivariable analysis (Table 1). 10-year death censored graft survival for AAV and anti-GBM was similar to IgAN and ADPKD (Fig1).
Conclusion
Long-term patient and graft survival for patients with ESRD due to AVV and anti-GBM after kidney transplant was good and similar to ESRD due to IgAN and ADPKD post transplantation.